BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250904T190000
DTEND;TZID=Africa/Nairobi:20250904T203000
DTSTAMP:20260423T211030
CREATED:20250902T070734Z
LAST-MODIFIED:20250902T074433Z
UID:40392-1757012400-1757017800@kesho-kenya.org
SUMMARY:Paediatric Bone Marrow Transplantation
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nDate & Time:📅 4th September 2025🕖 7:00 PM – 8:30 PM (EAT) \nModerator:Dr. Robert KimutaiConsultant Paediatrician & Haematologist-Oncologist\,MP Shah Hospital\, Nairobi \nSpeaker:Dr. Brian NderuConsultant Paediatrician & Haematologist-Oncologist\,Gertrude’s Children’s Hospital\, NairobiTopic: Paediatric Bone Marrow Transplant: Immense Possibilities \n[/vc_column_text][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_4YrYt-keT5yLYGrVG-811Q”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/bone-marrow-transplantation/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-02-at-9.30.03-AM-e1756796966321.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250807T190000
DTEND;TZID=Africa/Nairobi:20250807T203000
DTSTAMP:20260423T211030
CREATED:20250805T170900Z
LAST-MODIFIED:20250805T174804Z
UID:40344-1754593200-1754598600@kesho-kenya.org
SUMMARY:Cervical Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nSpeakers:\n\nDr. Dulcie Wanda\n\n\nClinical & Radiation Oncologist\nHead of Department\, Nakuru Regional Cancer Treatment Centre\n\nTopic: Radiotherapy in Management of Advanced Cancer of the Cervix. \n2. Dr. Edward Sang \n\nGynaecologist and Oncologist\, MP Shah Doctors Plaza\, Nairobi\n\nTopic: Surgical Techniques in Cervical Cancer \nModerator:\nDr. Afrin Fatima Shaffi \n\nGynecologic Oncologist\, Nairobi West Hospital\n\n[/vc_column_text][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_KINXix7MSqys9Q4p_rWZhQ”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cervical-cancer-3/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/08/WhatsApp-Image-2025-08-05-at-4.13.55-PM-1-e1754414483969.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250731T190000
DTEND;TZID=Africa/Nairobi:20250731T203000
DTSTAMP:20260423T211030
CREATED:20250414T202143Z
LAST-MODIFIED:20250806T123353Z
UID:24416-1753988400-1753993800@kesho-kenya.org
SUMMARY:Bone Marrow Transplant
DESCRIPTION:Date: 31 July 2025 | 7:00 – 8:30PM EAT \nModerator: Dr Matilda Ongondi \nDr. Rohini Radia – Bone Marrow Transplantation  \nBone marrow transplantation (BMT) is a potentially curative treatment for various blood cancers and benign hematologic conditions like sickle cell disease and aplastic anemia. It involves high-risk procedures requiring meticulous planning and long-term follow-up. \nThere are two main types: \nAutologous (using the patient’s own cells) and Allogeneic (using donor cells). Allogeneic BMT carries a higher treatment-related mortality (10–25%) and risk of complications such as graft-versus-host disease (GVHD)\, infections\, and infertility\, but it is the only curative option for several conditions. Autologous BMT is safer (TRM <5%) and commonly used in myeloma and lymphomas. \nPatient and donor selection\, conditioning protocols\, and GVHD prophylaxis are tailored individually. Long-term follow-up is essential\, especially due to chronic GVHD and relapse risks. In sickle cell disease\, allogeneic HSCT offers a potential cure but requires careful risk-benefit consideration. \nSuccess in BMT depends on early identification\, thorough preparation\, and sustained multidisciplinary care beyond the immediate post-transplant period.
URL:https://kesho-kenya.org/event/bone-marrow-transplant/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250801-WA0000-e1754042861975.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250724T190000
DTEND;TZID=Africa/Nairobi:20250724T203000
DTSTAMP:20260423T211030
CREATED:20250414T201502Z
LAST-MODIFIED:20250806T120327Z
UID:24407-1753383600-1753389000@kesho-kenya.org
SUMMARY:Sarcoma Care
DESCRIPTION:Bridging Gaps in Soft Tissue Sarcoma Care \nDate: 24 July 2025 | 7:00 – 8:30pm EAT \nModerator: Dr Rose Munge \nDr Mohammed Ezzi – Beyond the Visible: Unmasking Soft Tissue Sarcoma in the Heart of Africa\nSoft tissue sarcomas are rare malignant tumors of mesenchymal origin\, accounting for under 1% of adult cancers. A review at Kenyatta National Hospital showed large tumor sizes (avg. 13 cm)\, high recurrence (78%)\, and better outcomes with radical excisions. \nChemotherapy regimens in Ethiopia predominantly included Adriamycin-based combinations. However\, access to radiotherapy remains limited\, impacting outcomes. Timely radiotherapy\, as seen in Tanzania\, improves survival. \nKey gaps include limited resources\, lack of local treatment guidelines\, and minimal access to specialists. Future efforts should focus on building regional sarcoma centers\, local research\, and developing Africa-specific management guidelines.
URL:https://kesho-kenya.org/event/sarcoma/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/Sarcoma-Care-e1754481435270.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250717T190000
DTEND;TZID=Africa/Nairobi:20250717T203000
DTSTAMP:20260423T211030
CREATED:20250414T201147Z
LAST-MODIFIED:20250806T114844Z
UID:24403-1752778800-1752784200@kesho-kenya.org
SUMMARY:Endometrial Cancer
DESCRIPTION:Moderator: Dr Anisa Mburu\n1. Dr. Caroline Tonio – Advanced Endometrial Cancer\nDr. Tonio’s presentation highlighted significant advancements in the treatment of advanced and recurrent endometrial cancer. With rising incidence and poor outcomes in late-stage disease\, treatment has evolved from conventional chemotherapy to biomarker-driven strategies. \nMolecular subtyping\, as identified by the TCGA\, has enabled the use of immune checkpoint inhibitors (ICIs) and targeted therapies. Notably\, ICIs like dostarlimab and pembrolizumab show strong efficacy in dMMR/MSI-H tumors. Emerging combinations of ICIs with chemotherapy or TKIs are improving survival outcomes. The integration of molecular profiling is now essential in selecting optimal therapies. Future care will increasingly rely on predictive biomarkers to guide personalized treatment. \n2. Dr. Khadija Warfa – Endometrial Cancer Pathology and Surgical Staging\nDr. Warfa provided an overview of the pathology\, risk factors\, and staging of endometrial cancer. Most cases occur in postmenopausal women\, with abnormal bleeding as a common symptom. Risk factors include estrogen exposure\, obesity\, and genetic syndromes. \nDiagnosis relies on biopsy and imaging. Pathologically\, cancers are divided into Type I and II\, with molecular subtypes (e.g.\, POLE\, dMMR\, p53-abn) offering greater prognostic value. \nStandard surgical management involves hysterectomy with lymph node assessment. Sentinel lymph node biopsy is preferred in many cases due to lower complication rates. Minimally invasive approaches offer comparable survival outcomes with reduced morbidity.
URL:https://kesho-kenya.org/event/endometrial-cancer-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2025/04/unnamed-e1752574943250.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250710T190000
DTEND;TZID=Africa/Nairobi:20250710T203000
DTSTAMP:20260423T211030
CREATED:20250414T201718Z
LAST-MODIFIED:20250806T125314Z
UID:24409-1752174000-1752179400@kesho-kenya.org
SUMMARY:Prostate Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Date: 10 July 2025 | Time: 7:00 – 8:30PM EAT \nModerator: Dr Ahmed Komen \nDr Muigai Mararo – Management Algorithm for Metastatic Prostate Cancer\nDr Mararo presented a concise framework detailing oligometastatic local therapies (stereotactic radiotherapy or nodal resection)\, first‑line androgen‑deprivation therapy (continuous orchiectomy or LHRH analogue) combined with AR pathway inhibitors or docetaxel (with or without triplet combinations)\, radiotherapy for low‑volume disease\, and the sequencing of novel agents (second‑generation antiandrogens\, PARP inhibitors\, radioligand therapy) in castration‑resistant settings\, alongside essential supportive measures (bone protection\, multidisciplinary review). \nDr. Syokau Ilovi – Role of Germline Genetic Testing in Prostate Cancer\nAbout 10% of prostate cancers harbor pathogenic germline variants (notably BRCA1/2 and other HRR genes)\, prompting universal testing in metastatic disease and selective panels in high‑risk localized cases; implementation includes multigene panels\, variant classification (pathogenic\, VUS)\, genetic counseling\, cascade testing for relatives\, and periodic reclassification to inform personalized therapy and family risk management. \nDr. Mercy Gatua – Advances in Management of Metastatic Prostate Cancer: The Role of PARP Inhibitors\nPARP inhibitors exploit homologous recombination repair deficiencies (up to 30% of mCRPC\, especially BRCA2 mutations) by inducing lethal double‑strand DNA breaks; key trials (TOPARP\, PROfound\, TRITON3\, PROpel) demonstrate significant rPFS and OS benefits as monotherapy or combined with AR pathway inhibitors in germline/somatic HRR‑mutated cohorts\, supporting FDA/EMA approvals and integration into first‑line and later‑line mCRPC treatment algorithms. \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/prostate-cancer-6/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-07-07-at-11.29.37-AM-e1751892629661.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250703T190000
DTEND;TZID=Africa/Nairobi:20250703T203000
DTSTAMP:20260423T211030
CREATED:20250414T201819Z
LAST-MODIFIED:20250806T125526Z
UID:24411-1751569200-1751574600@kesho-kenya.org
SUMMARY:Lymphoma Management in Africa
DESCRIPTION:Date: 3 July 2025 | Time: 7:00 – 8:30 PM EAT \nModerator: Dr Beatrice Jepngetich \nDr. Anne Mwirigi – Relapsed/Refractory DLBCL \nDr. Anne Mwirigi presented a stage IVB germinal-center DLBCL case to illustrate why approximately 14% of Kenyan patients fail standard R-CHOP\, highlighting that true primary-refractory disease carries a median survival under nine months. She emphasized early risk stratification using IPI scoring\, interim PET imaging\, and molecular markers to identify high-risk individuals. For chemosensitive relapses\, salvage regimens such as R-GDP and R-ICE can bridge to autologous stem cell transplant; however\, CAR-T therapy and CD3×CD20 bispecific antibodies deliver the highest response rates. Practical recommendations included confirming residual disease with biopsy\, accelerating cellular therapy referral in primary-progressive cases\, and advocating for regional access programs to overcome cost barriers. \nDr. Jonathan Wawire – High-Grade B-Cell Lymphoma Entities \nDr. Jonathan Wawire decoded the WHO 5th-edition classification of high-grade B-cell lymphomas\, clarifying that a Ki-67 index ≥80% and dual MYC/BCL2 or BCL6 rearrangements define the most aggressive subtypes. He noted Kenya’s elevated prevalence of non-GCB and double-expresser lymphomas\, which correlate with poorer outcomes and necessitate intensified regimens. Key diagnostic insights included routine Ki-67 quantification\, Hans/Choi cell-of-origin algorithms\, and reflex FISH panels for precise double-hit detection. He stressed that accurate subclassification is essential for deciding when to intensify therapy beyond R-CHOP—such as DA-EPOCH-R—or to enrol patients in clinical trials\, ensuring truly personalized care for aggressive lymphoma in African settings.
URL:https://kesho-kenya.org/event/lymphoma-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-06-29-at-8.28.07-AM-scaled-e1751238405443.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250619T190000
DTEND;TZID=Africa/Nairobi:20250619T203000
DTSTAMP:20260423T211030
CREATED:20250414T202032Z
LAST-MODIFIED:20250806T125949Z
UID:24414-1750359600-1750365000@kesho-kenya.org
SUMMARY:Sickle Cell Disease
DESCRIPTION:Date: 19 June 2025 | Time: 7:00 – 8:30 PM EAT \nModerator: Dr Peter Oyiro \nProf. Jessie Githang’a – Sickle Cell Clinical Trials in Kenya \nProf. Jessie Githang’a emphasized the need for more SCD clinical trials in Africa\, where the disease burden is greatest. She outlined the underrepresentation of African populations in global trials and highlighted the benefits of local research\, including better understanding of drug efficacy\, safety\, and socio-genetic differences. She discussed ongoing and past trials in Kenya involving Hydroxyurea\, Crizanlizumab\, and gene therapies\, noting challenges like infrastructure gaps and limited expertise. Prof. Githang’a called for improved research capacity\, team collaboration\, and greater engagement with trial participants. \nDr. Doreen Mutua – Management of SCD in the 21st Century \nDr. Doreen Mutua reviewed modern SCD management\, highlighting the importance of early diagnosis\, health maintenance\, and Hydroxyurea therapy. She addressed common complications like stroke\, chronic pain\, and organ damage\, and emphasized early intervention to prevent progression. Transition of care for adolescents\, genetic counseling\, and curative options such as HSCT and gene editing were also discussed. Her presentation underscored the need for advocacy\, access to comprehensive care\, and integration of newborn screening into national systems.
URL:https://kesho-kenya.org/event/sickle-cell-disease-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-06-17-at-2.30.46-PM-e1750160210228.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250612T190000
DTEND;TZID=Africa/Nairobi:20250612T203000
DTSTAMP:20260423T211030
CREATED:20250414T201057Z
LAST-MODIFIED:20250806T113038Z
UID:24400-1749754800-1749760200@kesho-kenya.org
SUMMARY:Clinical Nutrition in Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr Catherine Nyongesa \nSpeakers & Topics: \n\nKennedy Okinda: Medical Nutrition Therapy Cases in Cancer Care – A Cross‑Sector Lens\nTraceyann Njeri Wacheke: Medical Nutrition Therapy in Survivorship & Secondary Cancer Prevention\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/clinical-nutrition-in-cancer/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-06-06-at-10.42.37-AM-scaled-e1749240060528.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250605T190000
DTEND;TZID=Africa/Nairobi:20250605T203000
DTSTAMP:20260423T211030
CREATED:20250414T200927Z
LAST-MODIFIED:20250622T142308Z
UID:24398-1749150000-1749155400@kesho-kenya.org
SUMMARY:Cancer Survivor's Day
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof John Weru \nSpeakers & Topics: \n\nMuthoni Mate: Tokenism in Cancer Survivor Involvement – Beyond Being the Face on a Brochure\nDr Mary Nyangasi: Beyond Remission – Best Practices in Survivorship Care Planning & Patient Navigation\nDr Esther Muinga: Palliative Care as a Pillar of Survivorship\n\nMuthoni Mate highlighted the issue of tokenism where survivors are symbolically included without influence. She called for shifting from consultation to co-design and recognizing survivors as experts by experience. Obstacles include medical jargon\, lack of trauma-informed engagement\, minimal institutional support\, and preference for academic voices. True engagement must be collaborative\, compensated\, and empowering\, allowing survivors to shape policy and practice. She urged stakeholders to move beyond the ‘face on the brochure’ and include survivors meaningfully in healthcare decision-making. \nDr. Nyangasi emphasized the critical role of survivorship care planning and patient navigation in ensuring long-term quality of life for cancer survivors. She outlined survivorship as a continuum beginning at diagnosis\, extending beyond acute care into surveillance\, psychosocial support\, and lifestyle guidance. Evidence from over 60 systematic reviews shows that patient navigation improves care access\, adherence to follow-up\, and satisfaction. Barriers in Kenya include weak health systems\, low awareness\, lack of funding\, and absence of integrated care protocols. There is urgent need for structured survivorship models and investment in navigation programs with proven return on investment. \nDr. Muinga presented palliative care as integral to survivorship\, aiming to improve quality of life through pain control\, emotional support\, and end-of-life care. She emphasized the interconnectedness of palliation\, prevention\, and health promotion. Effective survivorship care requires collaboration across disciplines and includes surveillance\, psychosocial screening\, and health education. Survivorship plans should empower patients and caregivers\, incorporate national policies\, and address financial and cultural challenges. She concluded that palliative care is not about dying—it’s about living fully post-treatment.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cancer-survivors-day/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-05-29-at-9.36.30-AM-e1748516449351.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250524T083000
DTEND;TZID=Africa/Nairobi:20250524T160000
DTSTAMP:20260423T211030
CREATED:20250414T200830Z
LAST-MODIFIED:20250622T142308Z
UID:24396-1748075400-1748102400@kesho-kenya.org
SUMMARY:EA Oncology Summit
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]\n\n\n    Download    PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/ea-oncology-summit-2/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2025/04/Screenshot-2025-05-20-130129-scaled-e1750167427791.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250522T190000
DTEND;TZID=Africa/Nairobi:20250522T203000
DTSTAMP:20260423T211030
CREATED:20250520T103711Z
LAST-MODIFIED:20250622T142307Z
UID:24535-1747940400-1747945800@kesho-kenya.org
SUMMARY:Multidisciplinary Approaches to Paediatric Brain Tumours
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr Alfred Odhiambo \nSpeakers & Topics: \n\nMr David L. Oluoch‑Olunya: Surgical Management of Paediatric Brain Tumours\nDr Michael Magoha: Endocrinological Management of Paediatric Brain Tumours\nDr Ahmed Korir: Radiation Therapy in Paediatric Brain Tumours\n\nMr. David Oluoch-Olunya presentation summary\n– Over 25 years\, Kenya has moved from fragmented care to growing multidisciplinary tumour boards in urban centres.\n– Key challenges remain: late diagnosis\, radiotherapy access disparities\, and poor survivorship follow-up.\n– Regional initiatives like the Brain Tumor Consortium of Africa (BTCoA) aim to standardize care and improve data sharing.\n– Priorities: expand MDT care to counties\, national paediatric tumour registry\, survivorship and rehab programs.\n– Kenya has made major strides\, but gaps persist in early detection\, diagnostics\, and referral systems. \nDr Ahmed Komen’s presentation summary \n– RT use depends on age\, tumour type/location\, other treatments\, and disease extent.\n– Modern RT techniques include 2D\, 3DCRT\, IMRT\, VMAT\, and proton therapy (where available).\n– RT aims: radical (curative) or palliative (symptom relief).\n– RT delivery to children requires precise planning and often sedation or anaesthesia.\n– Late effects of RT: cognitive decline\, growth delay\, hearing loss\, hormonal dysfunction\, secondary cancers.\n– Younger age (<7 yrs) and higher doses correlate with greater neurocognitive risks.\n– Proton therapy offers tissue-sparing benefits but has limited availability in LMICs.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/multidisciplinary-approaches-to-paediatric-brain-tumours/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/May-22nd-Poster-e1747737385167.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250515T190000
DTEND;TZID=Africa/Nairobi:20250515T203000
DTSTAMP:20260423T211030
CREATED:20250414T200633Z
LAST-MODIFIED:20250622T142308Z
UID:24390-1747335600-1747341000@kesho-kenya.org
SUMMARY:Bladder Cancer
DESCRIPTION:Moderator: Roselyne A. Okumu \nSpeakers & Topics: \n\nDr Melissa Reimers: Updates in the Management of Advanced Bladder Cancer\nProf Peter Mungai: Superficial Bladder Cancer Management\n\nManagement of Non-Muscle-Invasive Bladder Cancer (NMIBC) \n– NMIBC represents ~75% of new bladder cancer cases\, typically presenting with painless hematuria.\n– Diagnosis: Cystoscopy and TURBT; blue light cystoscopy improves detection.\n– Risk-based treatment approach:\n• Low/intermediate-risk: single post-op intravesical chemo (mitomycin C/gemcitabine)\n• High-risk: 6-week BCG induction ± maintenance\n– BCG-unresponsive NMIBC: radical cystectomy or emerging therapies.\n– Promising bladder-sparing agents: TAR-200 (gemcitabine) and TAR-210 (erdafitinib).\n– Trials (MoonRISe-3\, SunRISe-5) show >80% DFS in high-risk patients. \nUpdates in Advanced and Metastatic Bladder Cancer \n– Bladder cancer is the 4th most common male cancer globally.\n– Molecular profiling is critical: test for FGFR3 and HER2.\n– 1st-line standard: Enfortumab vedotin + Pembrolizumab (EV-302/KEYNOTE-A39).\n– Platinum-eligible: Cis/gem ± nivolumab; Carb/gem → Avelumab maintenance.\n– 2nd/3rd-line: Erdafitinib (FGFR+)\, T-DXd (HER2+).\n– Novel ADCs (Enfortumab\, Sacituzumab) offer superior outcomes to chemo.\n– Trial enrolment is encouraged for all patients. \nKey Clinical Takeaways \n– Intravesical innovation is changing NMIBC treatment beyond BCG.\n– Biomarker-driven therapy is now essential for managing advanced bladder cancer.\n– Routine molecular testing is critical for individualized care
URL:https://kesho-kenya.org/event/bladder-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/Bladder-Cancer.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250508T190000
DTEND;TZID=Africa/Nairobi:20250508T203000
DTSTAMP:20260423T211030
CREATED:20250414T200448Z
LAST-MODIFIED:20250622T144009Z
UID:24388-1746730800-1746736200@kesho-kenya.org
SUMMARY:Management of Indolent Lymphomas
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof Nicholas Otieno Abinya \nSpeakers & Topics: \n\nDr Samson Mutanda: Practical Approaches in Clinical Case‑Driven Exploration\nProf Shahin Sayed: Histopathology & Low‑Grade Lymphomas\nDr Matilda Ongondi: CT Treatment Algorithm – A Practical Approach\n\nDr. Samson Mutanda – presented case-based exploration of CLL management in Kenyan settings.\n– Key clinical points:\n• CLL is heterogeneous and often indolent; many patients start with watchful waiting.\n• Symptomatic cytopenias and disease progression warrant treatment.\n• Therapy included bendamustine\, rituximab\, venetoclax\, and novel agents like ibrutinib.\n– Highlighted diagnostic limitations due to access to FISH\, molecular testing\, and cost of targeted therapies.\n– Underscored importance of tailored care\, especially in young patients and those with co-morbidities. \nDr. Matilda Ongondi – Provided a clinical introduction to indolent lymphomas\, which are slow-growing B-cell neoplasms such as CLL/SLL\, follicular lymphoma\, and MZL.\n– Emphasized the necessity for clinical vigilance and long-term monitoring.\n– Stressed the need for diagnostic precision\, the role of immunophenotyping\, and the heterogeneity of clinical presentations.\n– Highlighted treatment considerations: watchful waiting\, targeted therapy\, and challenges in resource-limited settings. \nProf. Shahin Sayed – Reviewed WHO-HEM5 classification of indolent lymphomas\, emphasizing pathology-driven subtypes.\n– Covered key immunophenotypic markers: CD5\, CD23\, LEF1\, BCL2\, Cyclin D1\, etc.\n– Presented rare pediatric and adolescent cases\, illustrating diagnostic complexity and variability.\n– Detailed histologic signs of aggressive transformation (e.g. high Ki-67\, prolymphocytic features).\n– Outlined molecular diagnostics: del(11q\, 13q\, 17p)\, TP53 mutations\, IGHV SHM – all important for prognosis and treatment.\n– Discussed evolving terminology: classic FL\, follicular lymphoma with uncommon features (uFL)\, and follicular large cell lymphoma.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-indolent-lymphomas/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250505-WA0000-e1746479789592.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250424T190000
DTEND;TZID=Africa/Nairobi:20250424T203000
DTSTAMP:20260423T211030
CREATED:20250414T200348Z
LAST-MODIFIED:20250622T144124Z
UID:24386-1745521200-1745526600@kesho-kenya.org
SUMMARY:Advanced Ovarian Cancer
DESCRIPTION:Moderator: Prof Rose J. Kosgei \nSpeakers & Topics: \n\nProf Omenge Orang’o: Management of Epithelial Ovarian Cancer\nDr Peter Oyiro: PARP Inhibitors in Ovarian Cancer\nDr Charles Muteshi: Fertility Preservation in Ovarian Cancer\n\nEpidemiology and Diagnosis (Prof. Omenge Oran’go) \n– Ovarian cancer remains a significant cause of cancer mortality among women due to its asymptomatic nature in early stages.\n– Kenya sees many cases diagnosed at advanced stages (III/IV)\, primarily due to non-specific symptoms and lack of screening.\n– Important to understand pelvic anatomy and tumor spread patterns for accurate diagnosis and surgical planning. \nFertility Preservation in Ovarian Cancer (Dr. Charles Muteshi) \n– Fertility-sparing surgery should be considered in selected early-stage epithelial ovarian cancers (Stage I).\n– Discussion on embryo/oocyte cryopreservation for patients undergoing gonadotoxic treatment.\n– Emphasized need for multidisciplinary counseling and prompt fertility consultations to ensure oncologic safety and reproductive potential. \nRole of PARP Inhibitors (Dr. Peter Oyiro) \n– PARP inhibitors like Olaparib offer significant benefits in BRCA-mutated and homologous recombination-deficient (HRD) ovarian cancers.\n– SOLO-1 and SOLO-2 studies demonstrated prolonged progression-free survival and delayed recurrence in both frontline and maintenance settings.\n– 7-year follow-up data show sustained benefit\, with over 48% progression-free survival in Olaparib arms.\n– Low incidence of serious adverse events\, with anemia\, fatigue\, and nausea as the most common.\n– Highlighted integration into Kenya Cancer Treatment Guidelines and importance of HRD testing.
URL:https://kesho-kenya.org/event/advanced-ovarian-cancer/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250423-WA0000-e1745403823792.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250410T190000
DTEND;TZID=Africa/Nairobi:20250410T203000
DTSTAMP:20260423T211030
CREATED:20250407T135020Z
LAST-MODIFIED:20250622T144124Z
UID:24249-1744311600-1744317000@kesho-kenya.org
SUMMARY:Esophageal Cancer CME
DESCRIPTION:[vc_row][vc_column][vc_column_text]Esophageal Cancer CME – Experience from a Regional Cancer Centre \nModerator: Dr Tracy Irura \nSpeakers & Topics: \n\nDr Omar Abdihamid: Evolving Landscape of Esophageal Cancer Treatment\nDr Abdullahi Hadi: Optimising Diagnosis of Esophageal Cancer\nDr Mohamed Noor: Surgical Approaches to Esophageal Cancer\n\nDr. Noor Mohamed provided a historical evolution of esophageal cancer surgery from Czerny’s resection to modern minimally invasive techniques.\n– Surgical resection remains critical\, especially for early-stage and select advanced cases after neoadjuvant therapy.\n– Key considerations include thorough staging (OGD\, PET-CT\, EUS)\, patient optimization (nutrition\, glycemic control)\, and perioperative care.\n– Outcomes from global surgical databases: R0 resection rates up to 93%\, 30- and 90-day mortality rates at 2% and 4.5% respectively.\n– Challenges in Kenya include late presentation\, limited access to ICU care\, and lack of trained personnel.\n– Trials such as CROSS\, PreSANO\, and SANO are shaping modern surveillance versus resection decisions in select cases. \nDr. Omar Abdihamid – emphasized that most patients in Kenya present with locally advanced disease; male/female incidence is similar.\n– Immunotherapy has shifted paradigms: CheckMate 648 showed improved OS with nivolumab + chemotherapy or ipilimumab.\n– CROSS and ESOPEC trials guide perioperative regimens (carbo/taxol RT → surgery → nivolumab vs FLOT-based therapy).\n– Early-stage SCC may be treated with endoscopic resection if well-differentiated\, superficial\, and no lymphovascular invasion.\n– Radiotherapy regimens tailored by location: cervical tumors dose-escalated up to 60Gy; others typically 50.4Gy.\n– Garissa Cancer Centre approach includes advanced IMRT planning\, with regional data contributing to genomic and QoL research.\n– SANO trial supports non-inferiority of active surveillance post-chemoradiotherapy\, showing similar OS to surgery and better QoL.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/esophageal-cancer-cme/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME),Symposia and Workshops
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250407-WA0000-e1746480214833.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250403T190000
DTEND;TZID=Africa/Nairobi:20250403T203000
DTSTAMP:20260423T211030
CREATED:20250414T200239Z
LAST-MODIFIED:20250622T144124Z
UID:24384-1743706800-1743712200@kesho-kenya.org
SUMMARY:Head and Neck Cancer
DESCRIPTION:Moderator: Dr Angela Waweru \nSpeakers & Topics: \n\nDr Harish Nagaraj: Radiologic Imaging of Head & Neck Cancers\nDr Solomon Mutua: Role of PET/CT Scan in Head & Neck Imaging\n\nDr. Solomon Mutua emphasized the value of PET/CT in radiotherapy planning:\n– PET/CT allows for biologic imaging of tumors\, identifying hypoxic and metabolically active subvolumes.\n– Integration improves accuracy in delineating gross tumor volume (GTV)\, allowing for dose escalation while minimizing toxicity.\n– Particularly beneficial in cases with occult primaries\, equivocal CT/MRI\, and in adaptive RT strategies.\n– PET/CT-based contouring can reduce geographical misses and optimize nodal staging and treatment response.\n– Hypoxia imaging and dose painting are under investigation to further personalize radiotherapy protocols. \n 
URL:https://kesho-kenya.org/event/head-and-neck-cancer-3/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/Head-Neck-Cancer-e1749669290141.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250327T190000
DTEND;TZID=Africa/Nairobi:20250327T203000
DTSTAMP:20260423T211030
CREATED:20250611T191852Z
LAST-MODIFIED:20250622T142307Z
UID:38875-1743102000-1743107400@kesho-kenya.org
SUMMARY:Management of Kidney Cancer
DESCRIPTION:Moderator: Dr Jonathan Wala \nSpeakers & Topics: \n\nDr Amina K. Habib: Optimizing Kidney Cancer Care\nDr Patrick Mbuthia: Surgical Aspects of Kidney Cancer Management\n\nDiagnosis and Evaluation \n– RCC includes clear cell\, papillary\, chromophobe\, and rare subtypes.\n– Classic triad (flank pain\, hematuria\, mass) is rare and suggests late-stage disease.\n– Paraneoplastic syndromes present in ~30% of cases.\n– Imaging: Ultrasound (cystic lesions)\, MRI/CT (staging)\, and renal function tests.\n– Renal biopsy recommended for indeterminate lesions\, small masses for surveillance\, or metastatic confirmation. \nSurgical Management \n– Partial nephrectomy preferred in localized RCC for nephron-sparing and better long-term outcomes.\n– Thrombectomy improves survival in non-metastatic RCC with IVC involvement.\n– Cytoreductive nephrectomy and metastasectomy have roles in selected metastatic cases. \n Upper Tract Urothelial Carcinoma (UTUC) \n– Represents 5–10% of urothelial cancers\, commonly presents with hematuria.\n– Risk factors: smoking\, aristolochic acid\, arsenic exposure\, Lynch syndrome.\n– Diagnostic tools: CT/MRI\, cystoscopy\, urinary cytology\, retrograde pyelography\, ureteronephroscopy. \nManagement of UTUC \n– Low-risk: Endoscopic ablation + topical chemotherapy.\n– High-risk localized: Radical nephroureterectomy + bladder cuff removal\, postoperative intravesical chemotherapy.\n– Role of lymph node dissection and neoadjuvant chemotherapy is still being defined.
URL:https://kesho-kenya.org/event/management-of-kidney-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/Kidney-Cancer-e1749669450937.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250320T190000
DTEND;TZID=Africa/Nairobi:20250320T203000
DTSTAMP:20260423T211030
CREATED:20250611T192311Z
LAST-MODIFIED:20250622T142307Z
UID:38878-1742497200-1742502600@kesho-kenya.org
SUMMARY:Metastatic Colorectal Cancer
DESCRIPTION:Moderator: Dr Alex Muturi \nSpeakers & Topics: \n\nProf Olusegun Alatise: Surgical & Gastroenterology Perspectives in mCRC Management\nDr Andrew Odhiambo: First‑Line Therapy in mCRC – With or Without?\n\nGlobal and African Burden of CRC \n– CRC is the third most diagnosed cancer globally with an increasing burden in LMICs.\n– African patients show distinct molecular and clinical features\, including poor survival outcomes. \nPrinciples of Metastatic CRC Management \n– Multidisciplinary approach is essential; cure remains possible in select patients.\n– Surgery for metastasis should be guided by tumor biology\, technical feasibility\, and patient fitness.\n– Synchronous vs metachronous disease influences treatment sequencing. \nImaging and Surgical Considerations \n– Triphasic CT\, MRI with contrast\, and PET scans are standard.\n– Resectability is based on liver function and margin clearance\, not number/size of lesions. \nSurgical and Interventional Therapies \n– Options: surgical resection\, ablation\, HAIP chemotherapy\, two-stage hepatectomy\, ALPPS\, SIRT.\n– Preoperative chemotherapy helps with tumor downsizing and biology assessment but may impair liver function. \nGenetic and Prognostic Scoring \n– CRS\, GAME\, MRS\, and MSI/BRAF/TP53 profiles aid in stratifying patients.\n– Even high-risk patients can achieve long-term survival with careful selection. \nNewer Modalities \n– Thermal ablation is effective for small (<3cm) liver lesions.\n– Liver transplant is under investigation for select liver-only\, unresectable CRC. \nPeritoneal Carcinomatosis \n– Cytoreductive surgery + HIPEC has survival benefits in low PCI scores.\n– PRODIGE 7\, COLOPEC\, and PROPHYLOCHIP trials show limited benefit of prophylactic HIPEC \nConclusion \n– Metastatic CRC is treatable; coordinated\, case-specific care improves survival.\n– Early detection and healthcare system strengthening in Africa are vital.
URL:https://kesho-kenya.org/event/metastatic-colorectal-cancer-3/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/Metastatic-Colorectal-Cancer-e1749669731932.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250313T190000
DTEND;TZID=Africa/Nairobi:20250313T203000
DTSTAMP:20260423T211030
CREATED:20250611T192853Z
LAST-MODIFIED:20250622T142307Z
UID:38882-1741892400-1741897800@kesho-kenya.org
SUMMARY:Women in Oncology
DESCRIPTION:International Women’s Day: Women in Oncology \nModerator: Ms Benda Kithaka \nSpeakers & Topics: \n\nDr Catherine Nyongesa: Women in Leadership\nDr Khadija Warfa: Challenges Faced by Women in Oncology\nDr Gladwell Kiarie: Women in Oncology – How to Step Up the Game!\nProf Nazik Hammad: Harnessing Solidarity Between African Women in Oncology\n\nDr. Warfa discussed the multifaceted challenges faced by female oncologists in Africa\, including work-life imbalance\, gender-based microaggressions\, and structural sexism. She emphasized how family responsibilities\, limited mentorship\, and hierarchical work environments hinder progress. Solutions include flexible work arrangements\, inclusive leadership\, bias training\, and equitable opportunities for advancement. She also highlighted the importance of accurate gender representation in medical discourse and the superior clinical outcomes observed among female physicians. \nDr. Nyongesa focused on leadership development for women in oncology\, identifying critical attributes such as emotional intelligence\, vision\, resilience\, and effective communication. She encouraged mentorship\, strategic positioning\, and self-awareness. The presentation promoted intentional leadership development and emphasized that empowered women are key to empowering entire communities. \nDr. Kiarie highlighted systemic gender disparities in oncology\, such as underrepresentation in leadership\, editorial boards\, and conferences. She emphasized key challenges including lack of mentorship\, pay gaps\, burnout\, and societal biases. Proposed solutions included implementing mentorship and sponsorship programs\, advocating for inclusive policies\, prioritizing self-care\, and establishing supportive networks. She stressed the importance of visibility\, advocacy\, and proactive self-promotion for career progression
URL:https://kesho-kenya.org/event/women-in-oncology/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2025/06/Women-in-Oncology.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250306T190000
DTEND;TZID=Africa/Nairobi:20250306T203000
DTSTAMP:20260423T211030
CREATED:20250611T193255Z
LAST-MODIFIED:20250622T142307Z
UID:38887-1741287600-1741293000@kesho-kenya.org
SUMMARY:Updates in Myeloma Management
DESCRIPTION:Moderator: Dr Angela Mcligieyo \nSpeakers & Topics: \n\nDr M. B. Agarwal: Front‑line Therapy Trends\nDr Rohini Radia: Transplant‑Eligible vs Ineligible Patients\nDr M. D. Maina: Evidence‑Based Maintenance\nDr Boniface Githae: Contemporary Relapse Strategies\n\nDr. Maina addressed Smoldering Multiple Myeloma (SMM)\, emphasizing risk stratification to predict progression to active myeloma. The 2/20/20 IMWG model (based on FLC ratio and bone marrow plasma cell %)\, and the Spanish model using immunoparesis and plasma cell phenotyping\, were presented. Patients with ≥2 risk factors have a 50% chance of progression within 2 years. Ongoing efforts to integrate clinical and genomic risk markers aim to guide early therapeutic interventions. \nDr. Radia emphasized that autologous stem cell transplant (ASCT) remains the standard of care for transplant-eligible patients after induction chemotherapy. Key findings from major trials (IFM2009\, EMN02/H095) showed that ASCT improves progression-free survival (PFS) but does not significantly impact overall survival (OS). Post-ASCT maintenance therapy with lenalidomide improves PFS across all cytogenetic risk groups. CAR-T cell therapy and bispecific antibodies like Teclistamab and Elranatamab show promise in relapsed/refractory multiple myeloma (RRMM)\, offering new options with high response rates\, albeit with logistical and toxicity concerns. Kenyan real-world data shows promising survival outcomes with ASCT. \nDr. Githaiga presented practical approaches to diagnosis\, transplant eligibility\, and treatment selection. Diagnostic workups include comprehensive labs and bone marrow studies. For transplant-eligible patients\, quadruplet regimens like Dara-VRd followed by ASCT and lenalidomide maintenance are preferred. In high-risk cases\, bortezomib-based maintenance is advised. In non-transplant candidates\, extended triplet regimens followed by maintenance were recommended. He also highlighted Kenyan drug cost considerations and the importance of supportive care with antivirals\, antibiotics\, and bone-targeting agents.
URL:https://kesho-kenya.org/event/updates-in-myeloma-management/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/Updates-in-Myeloma-Management-e1749726883405.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250227T190000
DTEND;TZID=Africa/Nairobi:20250227T203000
DTSTAMP:20260423T211030
CREATED:20250611T193814Z
LAST-MODIFIED:20250622T142307Z
UID:38891-1740682800-1740688200@kesho-kenya.org
SUMMARY:AML: A Local Perspective
DESCRIPTION:Moderator: Prof Abinya \nSpeakers & Topics: \n\nDr Anne Mwirigi: Local Experience at a Tertiary Hospital\nDr Rohini Radia: The Role of Cytogenetics & Molecular Markers\nDr Peter Oyiro: Genomic Classification & Medical Oncology Pathways\nDr Beatrice Jepngetich: Panelist Discussion\nDr Mercy Gatua: Panelist Discussion\n\n Summary \nAML is genetically heterogeneous\, with most patients having multiple driver mutations.\n– WHO 2022 classification emphasizes genetic abnormalities over morphology or blast count.\n– Defining cytogenetic lesions like inv(16) or t(8;21) now suffice for diagnosis even with <20% blasts. \nDiagnostic Work-Up \n– FBC and peripheral blood smear\n– Bone marrow aspirate: morphology\, flow cytometry\, LAIP for MRD\n– Cytogenetics: Karyotyping and FISH\n– Next-Generation Sequencing (NGS): TP53\, NPM1\, etc.\n– Bone marrow trephine with immunocytochemistry. \nClinical Implications \n– Risk stratification through cytogenetics + molecular testing informs prognosis and treatment plan.\n– Favorable-risk patients may receive chemotherapy; adverse-risk patients considered for early allogeneic transplant.\n– MRD monitoring increasingly guides transplant decisions. \nTakeaways \n– AML is curable in a subset with intensive chemo + risk-adapted approach.\n– Precision oncology depends on accessible molecular diagnostics.\n– LMICs face challenges integrating NGS-based stratification.\n– Hypomethylating agents + Venetoclax offer promise in select patient groups.
URL:https://kesho-kenya.org/event/aml-a-local-perspective/
LOCATION:Aga Khan University\, Nairobi
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/A-Local-Perspective-e1749671173338.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250220T190000
DTEND;TZID=Africa/Nairobi:20250220T193000
DTSTAMP:20260423T211030
CREATED:20250217T194237Z
LAST-MODIFIED:20250622T142307Z
UID:38895-1740078000-1740079800@kesho-kenya.org
SUMMARY:International Childhood Cancer Day
DESCRIPTION:Moderator: Dr Alice Gichemi \nSpeaker & Topic: \nDr Terry Vik: Flow Cytometry for Rapid Diagnosis of Lymphoid Malignancies in Children & Teenagers \nGlobal Context \n– Childhood cancer cure rates: 80% in high-income countries\, ~30% in LMICs.\n– Barriers: delayed diagnosis\, treatment abandonment\, limited diagnostic access.\n– WHO/SIOP target: Double survival and save 1 million children by 2030. \n Leukemia Diagnosis in Kenya \n– Common signs: Pallor\, Pyrexia\, Purpura\, Pain (bony).\n– First-line tests: CBC and peripheral smear.\n– Many children present with Hgb < 7.0 — indicates late presentation. \nRole of Flow Cytometry \n– Globally standard for classifying ALL/AML.\n– In Kenya\, it’s reducing time-to-treatment\, especially in Burkitt Lymphoma (from 13.6 to 10.5 days).\n– Used on both bone marrow and peripheral blood samples for early diagnosis. \n Clinical Pilot Highlights \n– MTRH pilot expanding to 100 patients in 2026.\n– Focus: Feasibility of flow cytometry in peripheral blood diagnostics.\n– Goal: Develop scalable and SHIF/NHIF-coverable diagnostic methods. \nKey Clinical Takeaways \n– Recognize early signs of leukemia using the 4 P’s.\n– Flow cytometry is feasible and impactful in Kenya.\n– Early diagnosis can save lives — integration into local protocols is critical.
URL:https://kesho-kenya.org/event/international-childhood-cancer-day/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/International-Childhood-Cancer-Day-e1749670857260.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250206T190000
DTEND;TZID=Africa/Nairobi:20250206T203000
DTSTAMP:20260423T211030
CREATED:20250203T194848Z
LAST-MODIFIED:20250623T131746Z
UID:38898-1738868400-1738873800@kesho-kenya.org
SUMMARY:United for Cancer Prevention
DESCRIPTION:United for Cancer Prevention – People‑Centered Approaches in Healthcare\n\nModerator: Dr Douglas Nyandika\n\nSpeakers & Topics:\n\n 	Carol Wakesa: Community‑Led Prevention Strategies\n 	Dr Joan‑Paula Boit: Risk‑Reduction in Gynaecologic Cancers\n 	Dr Jerome Katamba: Behavioural Science & Cancer Prevention\n 	Dr Francis Makokha: The Socio‑Economic Determinants of Prevention Uptake\n 	Mr David Makumi: Building Survivor‑Led Advocacy Networks
URL:https://kesho-kenya.org/event/united-for-cancer-prevention/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/United-for-Cancer-Prevention-e1749671294368.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250123T190000
DTEND;TZID=Africa/Nairobi:20250123T203000
DTSTAMP:20260423T211030
CREATED:20250611T183601Z
LAST-MODIFIED:20250622T142307Z
UID:38855-1737658800-1737664200@kesho-kenya.org
SUMMARY:Cervical Cancer Care
DESCRIPTION:Advanced Ovarian Cancer \nModerator: Prof Rose J. Kosgei \nSpeakers & Topics: \n\nProf Omenge Orang’o: Management of Epithelial Ovarian Cancer\nDr Peter Oyiro: PARP Inhibitors in Ovarian Cancer\nDr Charles Muteshi: Fertility Preservation in Ovarian Cancer\n\nEpidemiology and Diagnosis (Prof. Omenge Oran’go) \n– Ovarian cancer remains a significant cause of cancer mortality among women due to its asymptomatic nature in early stages.\n– Kenya sees many cases diagnosed at advanced stages (III/IV)\, primarily due to non-specific symptoms and lack of screening.\n– Important to understand pelvic anatomy and tumor spread patterns for accurate diagnosis and surgical planning. \nFertility Preservation in Ovarian Cancer (Dr. Charles Muteshi) \n– Fertility-sparing surgery should be considered in selected early-stage epithelial ovarian cancers (Stage I).\n– Discussion on embryo/oocyte cryopreservation for patients undergoing gonadotoxic treatment.\n– Emphasized need for multidisciplinary counseling and prompt fertility consultations to ensure oncologic safety and reproductive potential. \nRole of PARP Inhibitors (Dr. Peter Oyiro) \n– PARP inhibitors like Olaparib offer significant benefits in BRCA-mutated and homologous recombination-deficient (HRD) ovarian cancers.\n– SOLO-1 and SOLO-2 studies demonstrated prolonged progression-free survival and delayed recurrence in both frontline and maintenance settings.\n– 7-year follow-up data show sustained benefit\, with over 48% progression-free survival in Olaparib arms.\n– Low incidence of serious adverse events\, with anemia\, fatigue\, and nausea as the most common.\n– Highlighted integration into Kenya Cancer Treatment Guidelines and importance of HRD testing.
URL:https://kesho-kenya.org/event/cervical-cancer-care/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/Cervical-Cancer-scaled-e1749667096838.jpg
END:VEVENT
END:VCALENDAR